The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

Teledermatology's growth in 2025 improved efficiency and accessibility, with virtual visits reducing costs and saving time for patients and doctors. Hybrid models combining live video and photo ...

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...

The use of an older medication at the time of surgery can reduce the need for red blood cell transfusions, according to a ...